Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

AUGMENTIN ES POWDER FOR ORAL SUSPENSION [SIN13201P]

Active ingredients: AMOXICILLIN TRIHYDRATE EQV (AMOXICILLIN FREE ACID) | POTASSIUM CLAVULANATE EQV CLAVULANIC ACID

View product's general information
Last updated on 9 October 2026

Product Info

AUGMENTIN ES POWDER FOR ORAL SUSPENSION

[SIN13201P]

Product information

Active Ingredient and Strength

AMOXICILLIN TRIHYDRATE EQV (AMOXICILLIN FREE ACID) - 600 MG/5 ML
POTASSIUM CLAVULANATE EQV CLAVULANIC ACID - 42.9 MG/5 ML

Dosage Form

POWDER, FOR SUSPENSION

Manufacturer and Country

GLAXO WELLCOME PRODUCTION - FRANCE

Registration Number

SIN13201P

Licence Holder

GLAXOSMITHKLINE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J01CR02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

Indications

AUGMENTIN ES should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.

AUGMENTIN ES is indicated for the treatment of paediatric patients with acute otitis media due to Streptococcus pneumoniae (penicillin minimum inhibitory concentration (MIC) less than or equal to ≤ 2 mcg/mL), Haemophilus influenzae (including beta-lactamase producing strains) and Moraxella catarrhalis (including beta-lactamase producing strains). Such patients are often characterised by antibiotic exposure for acute otitis media within the preceding 3 months, and are either aged ≤ 2 years or attend daycare.

Susceptibility to AUGMENTIN ES will vary with geography and time. Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.

Dosing

Dosage and Administration

Pharmaceutical form: Powder for oral suspension.

Paediatric patients 3 months and older:

The recommended dose for AUGMENTIN ES is 90/6.4 mg/kg/day in 2 divided doses at 12-hourly intervals for 10 days (see chart below). There is no experience in paediatric patients weighing more than 40 kg, or in adults. There are no clinical data on AUGMENTIN ES in children under 3 months of age.

Augmentin ES Dosage Table 1



AUGMENTIN ES does not contain the same amount of clavulanate (as the potassium salt) as any of the other AUGMENTIN suspensions. AUGMENTIN ES contains 42.9 mg of clavulanate per 5 mL whereas AUGMENTIN 200 mg/5 mL suspension contains 28.5 mg of clavulanate per 5 mL and the 400 mg/5 mL suspension contains 57 mg of clavulanate per 5 mL. Therefore, AUGMENTIN 200 mg/5 mL and 400 mg/5 mL suspensions should not be substituted for AUGMENTIN ES, as they are not interchangeable.

Hepatic Impairment

Administer with caution; monitor hepatic function at regular intervals.
There are insufficient data on which to base a dosage recommendation.

Renal Impairment

There are no dosing recommendations for AUGMENTIN ES in patients with renal impairment.

Method of Administration

To minimise the potential for gastrointestinal intolerance, AUGMENTIN ES should be taken at the start of a meal. The absorption of AUGMENTIN is optimised when taken at the start of a meal.

Note: SHAKE ORAL SUSPENSION WELL BEFORE USING.

Contraindications

Contraindications

AUGMENTIN ES is contraindicated in patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins.

AUGMENTIN ES is contraindicated in patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction.